Aspirin Dosing for Peripheral Arterial Disease Revascularization
For patients undergoing peripheral arterial revascularization, administer 325 mg of non-enteric-coated aspirin as a loading dose before the procedure if aspirin-naïve, or continue the current dose of 81-325 mg if already on aspirin therapy; post-procedure, maintain aspirin 81 mg daily indefinitely. 1
Pre-Procedure Loading Dose
For Aspirin-Naïve Patients
- Administer 325 mg of non-enteric-coated aspirin as soon as possible before the procedure 2, 1
- The optimal timing window is at least 2 hours before the procedure, preferably 24 hours in advance to achieve adequate platelet inhibition 2, 1
- Non-enteric-coated formulation is essential for rapid absorption and immediate antiplatelet effect 2, 1
For Patients Already on Aspirin
- Continue the current daily dose of 81-325 mg before the procedure 2, 1
- Do not discontinue aspirin in the perioperative period 1
Post-Revascularization Maintenance Dosing
Long-Term Aspirin Therapy
- Continue aspirin indefinitely after revascularization 2
- The preferred maintenance dose is 81 mg daily 2, 1
- While doses up to 325 mg daily are acceptable, 81 mg provides equivalent cardiovascular protection with significantly lower bleeding risk compared to higher doses 2, 1
Important caveat: High-dose aspirin (≥160 mg) is associated with increased bleeding risk without improved outcomes 2. The 2024 ESC guidelines specifically recommend aspirin 75-160 mg daily for symptomatic PAD patients 2.
Combination Antithrombotic Strategies
Dual Pathway Inhibition (Strongest Evidence)
- Adding rivaroxaban 2.5 mg twice daily to aspirin is recommended after endovascular revascularization to reduce major adverse cardiovascular events (MACE) and major adverse limb events (MALE) 1, 3
- This combination shows the strongest evidence for mortality benefit in PAD patients 4
Dual Antiplatelet Therapy (DAPT)
- After endovascular revascularization, clopidogrel 75 mg daily plus aspirin for 1-6 months is reasonable 1
- Following surgical revascularization with prosthetic grafts, DAPT may be reasonable for at least 1 month 1
- Long-term DAPT is not routinely recommended in PAD patients due to increased bleeding risk without clear benefit 2
Critical Timing Considerations
- If the 2-24 hour loading window cannot be met, administer aspirin "as soon as possible" before the procedure 2, 1
- Administering aspirin too close to the procedure may not achieve adequate platelet inhibition 1
- For patients receiving fibrinolytic therapy, clopidogrel loading should be 300 mg within 24 hours or 600 mg after 24 hours 2
What NOT to Do
- Avoid enteric-coated aspirin for loading doses due to delayed and reduced absorption 2, 1
- Do not use full-intensity oral anticoagulation (e.g., warfarin) as monotherapy for PAD without another indication (such as atrial fibrillation), as it increases bleeding risk without reducing MACE or MALE 1, 5
- Do not routinely use ticagrelor in PAD patients, as it is not recommended by current guidelines 2
- Do not treat asymptomatic PAD with antiplatelet therapy unless there are signs of clinically relevant atherosclerotic cardiovascular disease 2
Evidence Quality Note
The recommendations for aspirin dosing in PAD revascularization are primarily derived from extrapolation of PCI guidelines 2 and recent PAD-specific guidelines 2, 1. The ADAPTABLE trial demonstrated no difference in outcomes between 81 mg and 325 mg aspirin for secondary prevention in PAD patients, but confirmed higher bleeding rates with higher doses 6, 7, 8. The strongest PAD-specific evidence supports low-dose aspirin (81 mg) for maintenance therapy 2, 1, 9.